Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELATE: Elacestrant in Advanced Triple Positive Breast Cancer
NCT07612215Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of elacestrant in triple-positive breast cancer (TPBC) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Progression-Free Survival at 2 years. Started May 2026; status: recruiting.
02
Drugs
elacestrant
03
Conditions
triple-positive breast cancer (TPBC)
Beyond the preview
Go deeper on NCT07612215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612215.